Human fibronectin extra domain B as a biomarker for targeted therapy in cancer.
Relinde I Y LieverseDamiënne MarcusAlexander M A van der WielEvert J Van LimbergenJan TheysAla YarominaPhilippe LambinLudwig J DuboisPublished in: Molecular oncology (2020)
The extracellular matrix protein fibronectin contains a domain that is rarely found in healthy adults and is almost exclusively expressed by newly formed blood vessels in tumours, particularly in solid tumours, different types of lymphoma and some leukaemias. This domain, called the extra domain B (ED-B), thus has broad therapeutic potential. The antibody L19 has been developed to specifically target ED-B and has shown therapeutic potential when combined with cytokines, such as IL-2. In this review article, we discuss the preclinical research and clinical trials that highlight the potential of ED-B targeting for the imaging and treatment of various types of cancer. ED-B-centred studies also highlight how proper patient stratification is of utmost importance for the successful implementation of novel antibody-based targeted therapies.
Keyphrases
- emergency department
- extracellular matrix
- papillary thyroid
- clinical trial
- squamous cell
- endothelial cells
- healthcare
- high resolution
- primary care
- squamous cell carcinoma
- case report
- diffuse large b cell lymphoma
- cell therapy
- risk assessment
- binding protein
- quality improvement
- stem cells
- small molecule
- childhood cancer
- type iii
- photodynamic therapy
- human health
- phase ii